Skip to main content

Pfizer Q3 FY2026 results

  • PFE · NYSE
  • Pharmaceuticals
  • S&P 500
$28.89+0.21%Close 13 Nov 2026

Pfizer reported revenue of $16.6 billion, down 0.4% from a year earlier, net income of $3.24 billion and diluted earnings per share of $0.56 against $0.62 for the third quarter of fiscal 2026 (the three months to 27 Sep 2026).

From its quarterly report, filed 3 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 27 Sep 2026, against the three months to 28 Sep 2025. Amounts in USD.

Pfizer Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$16.58B$16.65B−0.4%
Gross profit$12.55B$12.48B+0.6%
Gross margin75.7%74.9%+0.8 pts
Operating income$3.67B$3.85B−4.6%
Operating margin22.1%23.1%−1.0 pts
Net income$3.24B$3.54B−8.4%
Diluted EPS$0.56$0.62−9.7%
Operating cash flow$5.38B$4.60B+16.8%
Capital expenditure$573.0M$602.0M−4.8%
Free cash flow$4.80B$4.00B+20.0%

Operating KPIs for the quarter

Pfizer operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Product revenue$13.3Bdown 4.8%
Royalty revenue$477.0Mup 9.4%
Pfizer CentreOne revenue$300.0Mdown 12.8%
Biopharma revenue$16.3Bdown 0.2%
Business Innovation Segment revenue$300.0Mdown 12.8%
United States revenue$10.6Bdown 0.8%
International Developed Markets revenue$3.6Bdown 1.4%
International Emerging Markets revenue$2.3Bup 3.1%

Earlier quarters

Pfizer results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202627 Sep 2026$16.58B−0.4%$0.56
Q2 FY202628 Jun 2026$15.03B+2.6%−$0.04
Q1 FY202629 Mar 2026$14.45B+5.4%$0.47
Q4 FY202531 Dec 2025$17.56B−1.2%−$0.29
Q3 FY202528 Sep 2025$16.65B−5.9%$0.62
Q2 FY202529 Jun 2025$14.65B+10.3%$0.51
Q1 FY202530 Mar 2025$13.71B−7.8%$0.52
Q4 FY202431 Dec 2024$17.76B+31.5%$0.07

More on Pfizer: financial statements · revenue · earnings per share

PFE's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.